

Index

- acquisitions 229
Adams, F. G. 207
adversarial model of
 government–industry relations
 207–8, 237
ageing population 229–30
Agency for Industry, Science and
 Technology (AIST) 215, 231
Agency for National Resources and
 Energy (ANRE) 223
agents/distributors 121, 122–5, 133,
 134, 135
agglomeration of profit centres 6, 7
‘agreed specialization’ 38
Aharoni, Y. 21, 68
Aliber, R. Z. 81
alliances, strategic 31–2, 138
 see also joint ventures
amakudari (‘descent from heaven’)
 213–15
Anderson, E. 28–9, 136, 139
anticipatory exports 79
Antimonopoly Act 234
Aoki, M. 10, 207, 208, 213
Artisien, P. F. R. 82, 93
Asia–Pacific region xxii, 177–89
 implications of SEM 183–8
 Pacific Asian Economic
 Community 187–8
 relations with EC 177–9
associated exports 79
Association of South East Asian
 Nations (ASEAN) 178, 183,
 187–8
Athos, A. G. 65

Baden-Fuller, C. 40
Bain, J. 63
balancing exports 79
Bartlett, C. 30, 60, 62, 66, 67
 ‘transnational’ 64, 65
Basic Industry Bureau 223
Bayliss, B. T. 30–1
Becker, J. 202
behavioural theory of the firm 68

Belli, R. D. 87
biotechnology 219, 231
Blodgett, L. L. 165
Boddewyn, J. J. 53–4
bounded rationality 68
Bridges, B. 189
Britain *see* United Kingdom
Brooke, M. Z. 31
Buchan, D. 188
Buckley, P. J. 5, 8, 21, 61, 62, 68,
 88, 136, 188
 collaboration 10
 culture 10, 44
 foreign market servicing 25, 26,
 78, 79, 81, 82, 93
 information management 71
 internalization 3, 40, 41, 52, 70;
 dynamics 8, 50–1; and
 market structure 43, 48
 joint ventures 192
 Kojima’s theory 38
 licensing sales 86
 management philosophy 65
 market 11
 multifunctional firm 9
 multinationality 20
 organizational development 31,
 69
 product cycle 39
 R&D 55, 56, 57, 66–7
 stages model 22, 23
 Third World 12
 transactioncost 28
building tax 196, 198
Burns, T. 62
Burton, J. 188
business organizations 214, 215
business strategy models 29–30
 see also management
Buzzell, R. D. 186, 188

‘C₁’ project 236
Canada–United States free-trade
 agreement 183
Cantwell, J. 62

- capabilities view of the firm 54
see also knowledge
- cartels 222, 234
- Casson, M. 11, 44, 61, 88, 136
 collaboration 10
 culture 10, 52, 65
 foreign market servicing 26, 78, 81, 82
 information management 71
 internalization 8, 40, 41; market 51, 70
 joint ventures 192
 management 49, 53
 multifunctional firm 9;
 separation of functions 48
 product life cycle 30, 39
 R&D 55, 56, 57, 66–7
 transaction cost 28
- Caves, R. E. 33
- Cecchini, P. 188
- centralization
 organizational development 69–70
 production 128, 130, 131, 134
- Chandler, A. 62, 63, 69
- channel management 9
- Chapman, M. 68
- chemical and allied industries 95, 96, 97
- Chemical Industry Committee 223–4
- Chesnais, F. 11
- China xxii, 178, 183, 187, 190–205
 development policy 191
 economic system 190–1
 open door policy 190–2, 202
 tax system *see* taxation
 tax treaty with UK 198, 199, 199–200, 200–1, 201
- Clegg, J. 12, 88
- 'close cases' 5–6, 6–7
- Coase, R. 11, 41, 61, 139
- Colchester, N. 188
- collaboration *see* cooperation
- collective enterprise income tax 193
- commitment 23–4, 54
- comparative static analyses 81
- compensation trade agreements 201
- competition
 changing world economy 4, 10
 government–industry relations 214
 internalization theory 53; Kojima and 42–4, 44; role of management 49–50
 Japan's protectionism 182
- competitiveness xxi, 115–36
 defining 115–16
 foreign market servicing strategy and 118–19
 market servicing policies 119–34; decorative paint 131–4; pharmaceuticals 121–31; scientific instruments 120–1, 122–5
- complementary assets 55–6
- conciliation of differences 214
- consensus-seeking relationships 214
- consultation 214
- Contractor, F. J. 31, 141
- contracts
 labour 41, 49–50
 management 27
- contractual joint ventures 27
 taxation in China 199–200
- control/strong influence 214
- cooperation 31–2
 China 190–205; form and taxation 197–201
 government–industry relations 214, 235–6
 response to changing world economy 4, 12, 13
 theory and 10
 typology of modes 27
- coordination of activities/approach 214
- co-production agreements 141
- costs
 fixed 39
 low 116
 transaction *see* transaction costs
 transformation 31
- Coughlan, A.T. 136
- Council for Petrochemical Industry Co-operation 223
- cultural advantage 52
- culture 44
 internationalization and 19–20
 and management 9–10, 65

- customers, tying in 50
 customs duties 193–4, 197
 Cyert, R. 68
- Davies, H. 25, 79, 86, 136
 Davignon, E. 221
 decorative paint industry 131–4,
 134
 deintegration 12, 13
 deregulation 4
 distribution 9
 networks as complementary assets
 55–6
 distributors/agents 121, 122–5, 133,
 134, 135,
 doctors 227
 Doz, Y. 32, 139
 drug prices 219, 226–7, 228, 230
 Drysdale, P. 189
 Dunning, J. H. 20, 61, 82, 87, 188
- Economic Council 209
 economic planning 209, 210–11,
 212
 efficiency 64
 Enderwick, P. 12
 entrepreneurship 10
 environment 11–12
 firm and 53–4
 equity joint ventures (EJVs) 140
 China and taxation 194, 198–9
 UK 145–6, 154, 160–8, 171;
 equity share-holding 163–8
 ethical pharmaceuticals 216
 Japanese market 227
 market servicing and
 competitiveness 121–6, 126
 see also pharmaceuticals industry
- Europe
 trade bloc 188, 189
 UK joint ventures in Western
 Europe 144–6, 170–1;
 equity shareholding 163,
 164; by industry 149, 150;
 by purpose 154–6, 157
- European Commission 222
 European Community (EC) 4
 Asian–Pacific relations 177–9
 British industry's sales 90, 91–3
 companies and SEM 185
 government–industry relations
 206, 207, 237; petrochemicals
 220–2; pharmaceuticals
 216, 217, 218, 231
 see also Single European Market
 Act
 European Free Trade Association
 (EFTA) 90, 91
 exploration consortia 141
 exporting 77
 competitiveness 118; decorative
 paint 131, 132, 133;
 pharmaceuticals 126–31;
 scientific instruments 121,
 122–5
 foreign market servicing 24–5,
 78–9, 117–18
 UK foreign sales structure *see*
 foreign sales structure
- externalization effect 78, 117–18
- 'fadeout' agreements 27
 Fair Trade Commission (FTC) 234
 Fallows, J. 207
 financial services 146, 171
 firm level economies of scale
 39–40
 fixed costs 39
 flexibility 136
 food, drink and tobacco industries
 95, 96, 97
 foreign direct investment 77
 competitiveness 118–19, 134,
 135; decorative paint
 131–4; pharmaceuticals
 127–31; scientific instruments
 121, 122–5
 foreign market servicing 24, 26,
 27, 78–9, 117–18
 UK foreign sales structure *see*
 foreign sales structure
- foreign enterprise income tax 193,
 194, 197–8, 199, 200, 201
 foreign market servicing xx–xxi,
 78–9, 117–18
 and competitiveness *see*
 competitiveness
 hypotheses from literature
 80, 81–3
 models and internationalization
 24–8

- foreign market servicing *cont.*
 shifts within mode 81
 UK foreign sales *see* foreign sales structure
- foreign sales structure, UK xx-xxi, 77-114
 exports 84-5, 98; by country 84, 90-5, 101, 104; by industry 85, 95-7, 107, 110
 foreign direct investment 87-9, 98; calculation of sales 87-8; by country 88, 89, 90-5, 100, 103; by industry 88, 89, 95-7, 106, 109
 foreign market servicing theory 78-84
 licensing 85-7, 98; calculation of sales 85-6; by country 86-7, 90-5, 102, 105; by industry 86, 95-7, 108, 111
 'fortress Europe' 179-80
 franchising 27
 functions of the firm 9
 coordination 41-2, 57, 67
 foreign market servicing models 26, 28
 internalization theory 48
 separation of 48
- Gatignan, H. 28-9
 Gelatt, T. A. 201
- generic pharmaceuticals 126
see also pharmaceuticals industry
- geographic distribution
 UK foreign sales structure 90-5, 98; exports 84, 90-5, 101, 104; foreign direct investment 88, 89, 90-5, 100, 103; licensing 86-7, 90-5, 102, 105
 UK joint ventures 143-6, 170-1; equity shareholding 163-5; by industry 149-51; by purpose 154-8
- Geringer, J. M. 140
 Ghemawat, P. 142, 143
 Ghoshal, S. 60, 62, 64, 65, 66, 67
 Glaxo 228
 global strategies 138
 globalization 83
 models 29-30
- government-industry relations 206-39
 empirical study 224-36
 industrial policy and 207-15; economic planning and state agencies 209, 210-11, 212; model of Japanese relations 209-15
 petrochemicals industry 215-16; global 220-2; Japan 222-4; research findings 231-6
 pharmaceuticals industry 215-20; global 216-18; Japan 218-20; research findings 226-31
- governments
 firms' relationships with 53-4
 pharmaceuticals industry and 126
 restrictions and internationalization 19
see also government-industry relations
- gradual learning theory 22-3
 Graham, E. M. 53, 64
 Grosser, K. 189
 growth of the firm 17-19
 internalization theory 50-1; management and 47-9
- Hallen, L. 19, 22
 Hamel, G. 32
 Harrigan, K. R. 137, 138, 140
 Health Insurance Fund System 226
 Hebert, L. 140
 Hedlund, G. 23, 62, 63, 68
 Hennart, J. F. 54
 Hergert, M. 142, 143, 151-3
 Heynitz, A. von 189
 Hirsh, S. 81
 history 65
 Hladik, K. J. 138
 Hood, N. 79
 Horst, T. O. 81
 Houston, T. 87
 Hymer, S. H. 14, 15, 20, 43, 48
- Ichimura, S. 207
 import regulatory tax 195-6
 income tax 193, 194-5, 196-7, 204

- 'indirect' tax credits 198, 199
- industrial and commercial
 - consolidated tax 192, 193, 195, 197, 198, 201
- industrial policy, Japanese 207–15
- Industrial Policy Bureau:
 - Industrial Structure Division 224
- Industrial Structure Council 223, 224
- industry 82
 - firms' relationship to 33
 - government–industry relations
 - see* government–industry relations
 - UK foreign sales structure by
 - 95–7, 98; exports 85, 95–7, 107, 110; foreign direct investment 88, 89, 95–7, 106, 109; licensing 86, 95–7, 108, 111
 - UK joint ventures 146–51, 171; contractual form 160–1; by purpose 158–9
- information management 68, 71
 - see also* knowledge
- intangible resources 54
- integration 4
 - US success 180–1
 - see also* Single European Market; trading blocs
- intensification 12, 13
- interest-representation model of
 - government–industry relations 208, 213, 237
- inter-firm relationships 32, 237
- intermediaries 121, 122–5, 133, 134, 135
- internal market 7, 47, 69–70
- internal venture capital market 56, 67
- internalization effect 78–9, 117–18
- internalization theory 3
 - comparison with international management 60–74
 - criticisms 5–8, 50–4
 - dynamics 8–9, 50–1
 - Kojima xix–xx, 38–46
 - and market structure 14, 15, 42–3
 - role of management 47–59
- international business theory xix, 3–16
 - ability to meet the challenge 10–13
 - compared with international management 60–74
 - contribution 5–10; criticisms 5–8; current state 8–9
 - empirical issues in world economy 4–5
- internationalization 12, 17–37, 82
 - approaches to 20–32; business strategy models 29–30; cooperation and networks 31–2; foreign market servicing models 24–8; organizational development models 30–1; product to cycle 21–2; stages models 22–4, 68–9; transaction cost models 28–9
 - barriers to 33–4
 - gains from 40–2
 - growth of the firm 17–19
 - Japanese pharmaceutical industry 228–9
 - as learning process 9–20
 - special factors in 19–20
- investment
 - restructuring 12, 13
 - tax incentives in China 197
- isomorphism 213
- Italy 91
- Jack, M. 201
- Japan 177
 - and European Community 178, 179, 181, 184
 - government–industry relations xxii, 206–39; economic planning and state agencies 209, 210–11, 212; industrial policy 207 15; model 209–15; petrochemicals industry 222–4, 231–6; pharmaceuticals industry 218–20, 226–31
 - Kojima's theory of foreign direct investment 38–46
 - protectionism 182–3
 - UK foreign sales 91, 92, 94

- Japan *cont.*
 UK joint ventures 144–6, 170;
 equity shareholding 163–5;
 by industry 149–51; by
 purpose 155, 156, 157
 Japan Development Bank 228
 Japan Health Sciences Foundation 228
 Japan Petrochemical Industry
 Association 233, 235
 Japanese mercantilism model 207
 Jehle, E. 192, 194, 195
 Jensen, M. C. 69
 Johanson, J. 31–2, 32, 54, 136
 stages model 22, 23, 68
 Johnson, C. 207, 231
 joint venture income tax 198, 199
 joint ventures 27
 characteristics of recent 138
 defining 140–1
 international business theory 6, 8
 Japanese pharmaceuticals industry
 219–20, 229
 motives for establishing 139
 taxation in China 198–200
 UK international xxi, 137–73;
 contractual form 160–2;
 data set 141–3; equity
 shareholding 163–8;
 industry characteristics
 146–51; number of partners
 162–3; purpose of joint
 venture 151–9; trends over
 time 143–6
 Jones, G. 52
 Jorde, T. M. 4
 Kaldor, N. 61
 ‘key capabilities’ 139
 Killing, J. P. 140
 Kindleberger, C. P. 5–8, 20
 Knickerbocker, F.T. 53, 83, 88
 knowledge
 economies of scope 70
 internal 54, 56, 67, 71
 transfer 64
 Kogut, B. 54, 62, 68
 Kojima, K. xix–xx, 38–46
 Kume, G. 184, 188
 Kverneland, A. 23, 68
 labour contracts 41, 49–50
 Langlois, R. N. 54
 Lawrence, P. R. 62
 learning 54, 62
 internationalization as learning
 process 70
 management 68–9
 stages models of
 internationalization 22–3
 legislation, China 191–2, 193, 203
 Li Jinyan 204
 Liberal Democratic Party, Japan
 213
 licensing 27, 77
 competitiveness 118, 131, 135
 foreign market servicing 24,
 25–6, 78–9, 117–18
 pharmaceuticals industry 218,
 219
 in technology 41–2
 UK foreign sales structure *see*
 foreign sales structure
 local manufacturing 127, 130, 131,
 134
 location 82
 endowments 42
 innovation and 20
 location effect 78, 117–18
 long-termism 136
 Lorange, P. 31, 141
 Lorsch, J. W. 62
 low costs 116
 Luostarinen, R. 68
 Lyles, M. A. 54, 62
 Lyons, P. L. 137
 Maaren, Th. van 201
 Maekawa report 215
 management xx, 7, 8, 47–59
 criticisms of internalization theory
 50–4
 culture and 9–10, 65
 international business theory
 compared with international
 strategic management
 60–74
 R&D xx, 55–7, 64, 66–7
 role in internalization theory
 47–59
 role in internationalization 34
 management contracts 27
 management learning 68–9

- management philosophies 65
 manufacturing
 local 127, 130, 131, 134
 UK foreign sales 84, 91–4, 96–7
 see also industry
 March, J. 68
 market 50–1
 foreign market servicing *see*
 foreign market servicing
 imperfections and management
 49
 internal 7, 47, 69–70
 international management 65
 network model 32
 relationship between firm and 33
 structure and internalization 14,
 15, 42–3
 marketing 9
 coordination with other functions
 41–2, 57, 67
 marketing-related joint ventures
 153–9
 Matsushita 66
 Mattson, L. G. 32
 McPherson, N. 189
 Meckling, W. H. 69
 Merck 228
 mergers 229
 Millington, A.I. 30–1
 Ministry of Agriculture 231
 Ministry of Health and Welfare
 (MHW) 216, 226–7, 228, 229,
 230, 230–1
 Ministry of International Trade and
 Industry (MITI) 215, 216, 226,
 230, 231
 role in petrochemicals industry
 222–4, 232–6
 minority holdings, foreign 27
 Mirza, H. 65, 188
 Mitsubishi Industrial Group (MIG)
 214, 215, 222
 Mitsui 222
 monopoly 42–4
 Morris, D. 142, 143, 151–3
 motor vehicles tax 196, 198
 multinationality 20
 Murakami, Y. 209
 National Health Insurance (NHI)
 listings 227
 pricing 228
 National Health Service, UK 217
 Neary, I. J. 213, 230
 networks
 distribution 55–6
 government–industry relations
 213–15, 236, 237
 internationalization 31–2
 Newbould, G. D. 21, 22
 newly industrializing economies
 (NIEs) 178, 182
 Nicholas, S. 81
 non-equity joint ventures (NEJVs)
 140–1, 145–6, 154, 160–3
 North American trade bloc 188, 189
 Nowak, P. 139
 number of partners 162–3, 171
 Ohmae, K. 177, 188
 oil prices 220, 223–4
 Organization for Economic
 Cooperation and Development
 (OECD) 141
 organization of the firm 6, 7
 organizational development 69–70
 models of internationalization
 30–1
 Ouchi, W. G. 208
 over-the-counter (OTC) drugs 227
 Ozawa, T. 189
 Pacific Asian Economic Community
 187–8, 189
 see also Asia–Pacific region
 paint, decorative 131–4, 134
 Pan-European companies 184, 185
 Park, S.-J. 189
 partners, number of 162–3, 171
 Pascale, R. T. 65
 Pass, C. L. 8, 9, 26, 39, 36
 ‘passive income’ 194
 Patrick, H. T. 207
 Pearce, R. D. 78
 Penrose, E. T. 18, 54, 61
 personal income tax 194–5, 204
 Petrochemical Industrial Capacity
 Subcommittee 224
 petrochemicals industry 206,
 215–16

- petrochemicals industry *cont.*
 global 220–2
 government–industry relations
 research findings 231–6
 Japan 222–4
 Petroleum Council 223–4
 Pfeffer, J. 54, 139
 Pfizer 228
 pharmaceuticals industry 206,
 215–20
 competitiveness 121–31, 134
 global 216–18
 government–industry relations
 research findings 226–31
 Japan 218–20
 Philips 66
 planning
 economic in Japan 209, 210–12
 firms' as internal constraint 33
 plant level economies of scale 39,
 40
 political behaviour, firms' 53–4
 political change 4, 11
 Pomp, R. D. 201
 Porter, M. E. 18, 32, 136, 189
 firm–industry relationship 33
 globalization model 29, 30, 83
 international management 63
 protection 182
 Poynter, T. A. 30
 Prahalad, C. K. 32
 Prescott, K. 8, 9, 25, 26, 39, 136
 presence effect 79
 press releases 143
 prices/pricing
 cartels 222, 234
 drugs 219, 226–7, 228, 230
 oil 220, 223–4
 shadow pricing 7, 70
 transfer pricing 42
 principal–agent problems 54, 69
 product cycle 62
 model of internationalization 20,
 21–2
 switching point 21–2, 39
 product development, joint ventures
 related to 151–9, 161–2
 product differentiation 116
 product groups, coordination across
 48
 production 9
 centralization 128, 130, 131, 134
 coordination with other functions
 41–2, 57, 67
 co-production agreements 141
 production capacity, petrochemical
 220–2, 223, 232–4
 profit centres, agglomeration of 6, 7
 protectionism 179, 179–83
 psychic distance 19–20
 purchasing
 concentration of purchasing power
 217–18
 internal 57
 purpose of joint venture 151–9,
 161–2, 171
 Quelch, J. A. 186, 188
 rationality model of
 government–industry relations
 207, 213, 236–7
 rationalization 12, 13
 Reddaway Report 80
 relocation 12, 13
 remittance tax 19
 rent-seeking behaviour 49
 research, fundamental 235–6
 research and development (R&D)
 9, 62
 coordination with other functions
 41–2, 57, 67
 management xx, 55–7, 64, 66–7
 pharmaceuticals industry 126,
 216–17; Japanese expenditure
 228
 stages of innovation 56, 66–7
 UK joint ventures 151–9
 research partnerships 141
 resource availability 33
 resource dependency theory 139
 responsiveness 64
 restructuring
 industrial *see*
 government–industry
 relations
 world economy 5; firms' responses
 12, 13
 Richardson, G. B. 31
 Roche, E. M. 71
 Rolander, D. 62, 63
 Rome, Treaty of 222

- Root, F. R. 136
 Rosovsky, H. 207
 Rosson, P. 81
 Rugman, A. M. 69
- safety 226
 Salancik, G. 139
 sales concentration 217
 sales subsidiaries 121, 122–5, 133, 134, 135
 Savara, A. M. 136
 Saxonhouse, G. 207
 scale economies 8, 39–40, 44
 Scherer, F. M. 48
 scientific instruments 120–1, 122–5, 134
 scope, economies of 48
 separation, functional 48
 service provision joint ventures 151, 152, 153–9, 171
 services 44
 shadow pricing 7, 70
 shareholding, equity 163–8, 171
 Shepherd, R. 84
 shipbuilding 95–6
 Showa Denko 222
shukko ('loan of personnel') 213
 Simon, H. 68
 Single European Market Act (SEM) xxii, 11, 177–89
 implications for Asian-Pacific firms 183–8
 protectionism 180–3
 rationale 179–80
 small firms 18–19
 social change 4, 11–12
 social security payments 196
 Spain 91
 Sparkes, J. R. 188
 specialization, agreed 38
 stages models
 internationalization 22–4, 68–9
 organizational development 30–1
 Stalker, G. M. 62
 state agencies 209, 212
 see also government–industry relations
 Stiglitz, J. 70
 Stopford, J. M. 30, 40, 63
 strategic alliances 31–2, 138
 see also joint ventures
 strategic management *see* management
 strategy models 83
 subcontracting, international 27
 subsidiaries
 manufacturing 127, 130, 131, 134
 sales 121, 122–5, 133, 134, 135
 wholly owned 27; taxation in China 197–8
 Sumitomo 222
 Swedish School 82
 switches, timing of 81
 switching point 21–2, 39
- Takeda 228
 tax sparing credits 198, 199, 200, 201
 taxation
 China 191–203, 204; affecting foreign enterprises and individuals 194–6; compensation trade agreements 201; contractual joint ventures 199–200; effects on foreign investment 192–4; equity joint ventures 198–9; incentives 196–7; measures to promote foreign investment 202–3; transfer of technology agreements 200–1; wholly owned ventures 197–8
 Japan 228
 teams/team-building 52–3
 technological change
 joint ventures and 138
 world economy 4, 11; firms' response 12, 13
 technology
 licensing-in vs developing 41–2
 'spinning off'/'buying out' 52
 value of 55–6
 see also research and development
 technology transfer agreements 200–1
 Teece, D. J. 4, 55
 Temporary Measures Law for the Structural Adjustment of Specific Industries 224, 232–4
 Thatcher, M. 181–2

- Third World 5, 12–13
 Thurwell, J. 21, 22
 time dimension
 internalization theory 51–2
 internationalization 33
 UK joint venture 143–6, 170–1;
 by industry 148–9; by
 purpose 153–6
 total foreign sales (TFS) xxi, 77
 tournament theory 70
 trade
 compensation trade agreements
 201
 political changes and 4
 SEM *see* Single European
 Market Act
 UK foreign sales *see* foreign
 sales structure
 trading blocs 180, 183, 188
 transaction costs
 internalization theory and
 management 48, 49–50
 joint ventures 139
 models of internationalization
 28–9
 transfer pricing 42
 transformation costs 31
 ‘transnational’ 64
 constraints on building 65
 ‘triad power’ 177
 Turnbull, P. W. 68
 ‘turnkey ventures’ 27
 Tyson, L. 207
- United Kingdom (UK) 25
 book value of foreign direct
 investment 99
 foreign sales structure *see*
 foreign sales structure
 government–industry relations
 xxii, 217
 joint ventures *see* joint ventures
 pharmaceuticals industry 216,
 217
 and protectionism 181–2
 tax treaty with China 198, 199,
 199–200, 200–1, 201
- United States of America (USA)
 177, 178
 free-trade agreement with Canada
 183
- integration and competitiveness
 180–1
 and SEM 179
 UK foreign sales structure 91, 93
 UK joint ventures 170–1; equity
 shareholding 163, 164; by
 industry 149, 150; by
 purpose 154–6, 157; over
 time 143–6
- Vahlne, J. E. 22, 54, 68, 136
 Value Added Taxation (VAT) 193
 value of technology 55–6
 venture capital market, internal 56,
 67
 Vernon, R. 81
 product cycle 20, 21–2, 51, 62,
 68; switching point 21–2,
 39
 Viesti, G. 137–8
 Vogel, E. 207
 Volkswagen 6–7
 Volvo 6–7
- Watanabe, S. 188
 Watts, D. 232
 Weidersheim-Paul, F. 19, 22, 23,
 68
 Weinshall, T. D. 9
 Welch, L. S. 68
 Wells, L. T. 19, 63
 White, G. 209
 White, R. G. 30
 wholly owned subsidiaries 27
 taxation in China 197–8
 Willard, G. 136
 Williamson, O. E. 61, 139
 withholding tax 198, 199, 200, 201
 Wolferen, K. van 207, 213, 232–3
 World Bank 190
 world economy trends 4–5
 theory’s ability to meet challenges
 10–13
- Young, S. 21, 30, 65, 79
- Zander, U. 54, 62
 Zysmon, J. 207